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Patients with longstanding ulcerative colitis
in remission do not have more irritable
bowel syndrome-like symptoms than
controls
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Abstract
Background: Irritable bowel syndrome (IBS) is more common in patients with ulcerative colitis (UC) than expected.
The prevalence of IBS in patients with UC with longstanding disease is not known. We investigated the prevalence
of IBS-like symptoms in patients with UC in remission and longstanding disease in comparison to control subjects.
Methods: Sixty-eight patients with UC and 33 patients with hereditary familiar colon cancer and who underwent
colonoscopy surveillance were included. Faecal calprotectin (FC), Gastrointestinal Symptoms Rating Scale-Irritable
Bowel Syndrome (GSRS-IBS) and Hospital Anxiety and Depression scale were fulfilled prior to endoscopy. UC in
remission was define by steroid-free clinical remission, a Mayo Score ≤ 1 on endoscopy, a FC ≤ 200 μg/g and no
significant active inflammation on colon biopsies.
Results: Fifty-five UC patients met the criteria for being in remission. The median disease duration was 17 years. The
patients with UC in remission tended to have lower scores on total GSRS-IBS score (6 vs 10.5; p = 0.062) and lower or
equal scores on all specific IBS symptoms in comparison to controls. There was a moderate but significant correlation
between diarrhoea scores and FC levels (in the span≤ 200 μg/g) (rs 0.38; p = 0.004) in the UC in remission group.
Conclusion: Patients with UC with longstanding disease and in remission do not have more IBS symptoms than controls.
In UC patients in remission the FC level in the lower span showed a moderate correlation to symptoms of diarrhoea.
Keywords: Irritable bowel syndrome, Inflammatory bowel disorder, Ulcerative Colitis
Background
Ulcerative colitis (UC) is a chronic inflammatory bowel
disease affecting the colon and rectum with an annual
incidence of 9–20 per 100 000 in the western population
[1, 2]. The natural history of UC is episodic with quiescent
periods interspersed with active flare-ups. Although most
patients have a decrease in symptoms over time [3] UC is
a lifelong condition with potentially negative impacts on
the quality of life [4]. Even in patients with UC in objective
remission gastrointestinal symptoms are common. A
meta-analysis showed that approximately 30% of patients
with UC in remission reported irritable bowel syndrome
(IBS)-like symptoms [5], which is more than twice as high
as the prevalence in a normal population [6]. However
there is some evidence that IBS-like symptoms in patients
with UC may be due to inflammatory activity that is not
apparently seen on endoscopy. For example, UC patients
in remission with IBS-like symptoms had higher levels of
calprotectin in faeces than patients without IBS symptoms
[7]. Most studies investigating the occurrence of IBS-like
symptoms in patients with UC in remission have defined
remission using either clinical or endoscopic scores [5],
and only a few studies have investigated IBS-like symp-
toms in patients using more strict criteria for remission
(based on endoscopic and faecal markers) [8]. A faecal
calprotectin (FC) cut-off level of 50–150 μg/g helps to
discriminate patients with functional gastrointestinal
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disease from those patients with inflammatory bowel dis-
order (IBD) [9, 10].
To date, we lack a consensus on how to define remis-
sion in patients with UC using faecal markers. A FC of ap-
proximately 120–200 μg/g has been suggested [11–13].
The patients included in previous studies investigating
IBS-like symptoms in patients with UC have either had a
short duration of the disease or there has been a mixture of
patients with short and long duration [5, 8, 14]. Currently,
there is a lack of data in the literature regarding what
happens over time with IBS symptoms in patients with UC.
Do patients with longstanding UC continue to have signifi-
cant IBS-like symptoms? The primary aim of this study was
to compare the prevalence of functional gastrointestinal
symptoms including IBS-like symptoms in patients with UC
in remission (with a more accurate assessment of remission)
and longstanding disease with control subjects. Secondary
aims were to investigate whether low-grade inflammation
(in the span of a FC < 200 μg/L) correlates with IBS-like
symptoms, and to determine whether symptoms of anxiety
and depression have an impact on IBS-like symptoms.
Methods
Patients and control subjects
Between May 2007 to February 2013 all patients with UC
who underwent a surveillance colonoscopy at the endos-
copy unit at Umeå University hospital were invited to par-
ticipate in the study (n = 216). At our clinic all patients with
an extensive UC are invited to enter a surveillance colonos-
copy program for ten years after diagnosis with the aim to
detect dysplasia and early cancer. Control subjects were re-
cruited from patients who underwent a surveillance colon-
oscopy due to hereditary familiar colon cancer.
Both patients and controls were sent an informed con-
sent, questionnaires and a faecal calprotectin test 4–6
weeks before the planned colonoscopy.
Questionnaires
The Gastrointestinal Symptom Rating Scale-IBS (GSRS-IBS)
was used to evaluate IBS-like symptoms. GSRS-IBS is a vali-
dated self-assessment instrument for assessing IBS symp-
toms and it consists of 13 items, each using a Likert scale
(0–6 points) spanning from no symptoms to very severe
symptoms [15, 16]. The items are grouped into symptom
clusters for abdominal pain (two items), bloating (three
items), constipation (two items), diarrhoea (four items) and
satiety (two items).
In addition to the GSRS-IBS, the study subjects pro-
vided information about concurrent medications, previous
operations and filled in the Hospital Anxiety and Depres-
sion Scale (HADS). HADS is a validated instrument ori-
ginally designed to screen for symptoms of anxiety and
depression among patients with somatic disease [17, 18].
It consists of 7 four-point Likert items each for anxiety
and depression. We used the HADS because it exhibits
high sensitivity in detecting symptoms of anxiety and
depression, it is thoroughly validated, it is easy to fill in,
and we have used it in previous research addressing the
relationship between anxiety and depression with gastro-
intestinal symptoms [19].
Faecal Calprotectin (FC)
Calprotectin is a calcium and zinc binding protein. It is
mainly found in the cytoplasm of neutrophils but is also an
abundant protein in monocytes and macrophages [20]. FC
is resistant to bacterial degradation and is stable in stool at
room temperature up to 7 days. FC correlates well with gut
inflammation and is an established marker used for screen-
ing and for monitoring patients with IBD [21, 22]. In the
present study the samples for FC were sent to the accredited
Department of Laboratory Medicine, Clinical Chemistry,
Umeå University Hospital, and were analysed using the
CALPRO® Calprotectin ELISA Test (ALP) according to the
manufacturer (Calpro AS, Norway). The study participants
were asked to collect the stool sample the day before the
bowel preparations for the colonoscopy were scheduled.
Colonoscopy
The colonoscopy was performed as clinical routine and
by different endoscopists. At least 18 biopsies from a
minimum of nine locations were taken in each patient,
and the specimens were judged by experienced patholo-
gists. All endoscopists and pathologists were blinded by
the outcome of questionnaires and the level of the FC.
Definition of UC remission
The patients were defined as being in remission if all of
the following four criteria were met: no present flare-up
or steroid treatment, a Mayo Score ≤ 1 on endoscopy [23],
a FC ≤ 200 μg/g, and no significant active inflammation
on colon biopsies. No significant active inflammation on
colon biopsies was defined as inactive (no granulocytic re-
action was found either in epithelial or stromal compart-
ments) or mild (existence of pericryptitis and eventually a
few granulocytes in crypt, and/or surface epithelium) [24].
Records from the departments of medicine, surgery and
endoscopy units were checked to confirm UC diagnosis,
to establish clinical remission and to confirm that the col-
onoscopy was performed in the surveillance program. The
records of the control subjects were searched to exclude a
coincident gastrointestinal disease (including a change in
bowel habits the year before the endoscopy) and that the
colonoscopy was performed in the surveillance program.
Exclusion
During the study period 216 patients with UC were in the
surveillance program, and 80 patients accepted to partici-
pate in the study. Eleven patients were excluded due to
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missing FC tests, one patient was excluded due to a recent
liver transplantation, and 13 patients did not meet the
criteria for being in remission thus resulting in 55 patients
with UC for analysis (Fig. 1). Forty-two control subjects
accepted to participate in the study and 9 of these were
excluded due to missing FC tests, thus resulting in 33 con-
trol subjects for the analysis.
Statistical analysis
SPSS (version 22) was used for data analysis. Student t-test
was used for parametric comparisons. Mann-Whitney U
non-parametric test was used to evaluate differences
between groups. The Spearman non-parametric test was
used to evaluate correlations. All tests were 2-sided and with
a 5% significance level.
Results
Basal characteristics
Table 1 shows the basal characteristics of patients and con-
trols and the Montreal classification [25] for the patients. In
comparison to the control subjects, there were significantly
fewer women among the patients with UC in remission.
The patients with UC in remission had low levels of FC but
still significantly higher FC levels than the control subjects.
IBS-like symptoms in patients with UC and controls
There was no difference in the total GSRS-IBS scores be-
tween patients with UC in remission and controls (Table 2).
Symptoms of constipation were significantly higher in the
controls in comparison to the UC patients in remission but
there were no differences in the other symptom clusters.
Correlations between faecal calprotectin and IBS-like
symptoms
There was no significant correlation between FC levels and
total GSRS-IBS score in patients with UC in remission
(Table 3). When analysing the different symptom clusters
there was a significant correlation between FC and symp-
toms of diarrhoea in the patients with UC in remission. In
the control group there were no statistically significant
correlations between FC and total GSRS-IBS scores or any
of the symptom clusters in the control group.
Correlation between IBS-like symptoms and symptoms of
anxiety/depression
There were significant correlations between total GSRS-
IBS score and both HADS subscores (anxiety and depres-
sion) in the patients with UC in remission (Table 4). The
strongest correlation was between anxiety and bloating
followed by anxiety-constipation, depression-satiety and
anxiety-diarrhoea. In the control subjects there were no
significant correlations between GSRS-IBS scores and
HADS scores, although there were borderline significant
correlations between anxiety-bloating and anxiety-satiety.
Discussion
IBS-like symptoms are common in patients with UC with
active and inactive disease [5]. However, the present study
shows that patients with longstanding disease in remission
do not have more IBS symptoms than control subjects. The
IBSEN study described the natural course of UC during a
five year period after diagnosis, and found that a majority
of the patients had a decrease in disease activity over time
[3]. Our study may indicate that IBS-like symptoms also
diminish over time. Although poorly described in most
previous studies, the disease duration in UC patients in
Fig. 1 Flow diagram for the selection of the patients with ulcerative colitis
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remission with IBS-like symptoms has been similar to those
without IBS-like symptoms. The reported mean duration of
UC disease in previous studies is between 3 and 12 years
[7, 8, 14, 26–28], which is shorter than the median disease
duration in our UC patients. Another explanation to the
low scores on IBS-like symptoms among patients with UC
in remission in our study could be the rigorous criteria we
used for defining remission. In previous studies there has
been a wide heterogeneity for criteria defining remission. A
combination of clinical judgement and endoscopic scores to
define remission are commonly used [7, 8, 14, 26, 28–33].
In our study, in addition to endoscopy and clinical judge-
ment, we also included a low FC level and the presence of
no significant inflammation on the biopsy from the colon to
define remission. Perhaps the reported high frequency of
IBS in patients with UC in previous studies could partly be
explained by the presence of low-grade bowel inflammation.
For example, Keohane et al. [7] described that patients with
UC in remission and IBS-like symptoms had much higher
FC levels than the patients without IBS-like symptoms
(591 μg/g vs 229 μg/g). Also Berril et al. [28] found a trend
toward a higher median FC in UC patients in clinical remis-
sion with IBS-type symptoms. Interestingly, the present
study also showed that even in the lower span of FC
(≤200 μg/g) there was a moderate significant correlation be-
tween FC and symptoms of diarrhoea. One can therefore
argue that even in the presence of low-grade inflammation
there could be reasons to optimize treatment in patients
with UC (especially if they report diarrhoea symptoms).
There could also be alternative explanations to the re-
ported low scores on IBS in patients with longstanding
UC. The low degree of symptoms could be due to the
adaption at the gut and at the central level leading to “a
normalizing of gut discomfort” or down-regulation of
gut stimuli as times goes on. In 30–50% of patients with
IBS the symptoms decrease or disappear with time [34].
The pathogenesis of IBS is unknown and is probably
complex involving multiple mechanisms. Low grade in-
flammation, intestinal dysbiosis, altered intestinal perme-
ability, visceral hypersensitivity and brain-gut interplay
between psychological distress and gut signals have been
Table 1 Basal characteristics: Patients with ulcerative colitis in
remission and controls
Ulcerative colitis in




Mean age years (SD) 49 (14.2) 52 (10.2) 0.27
Women 45% 60% 0.03*
Median disease














37 (42) 21 (18) <0.02*
*Statistically significant
Ulcerative colitis in remission was defined by steroid-free clinical remission,
a Mayo Score ≤1 on endoscopy, a fecal calprotectin ≤200 μg/g and no
significant active inflammation on colon biopsies
Table 2 Irritable bowel syndrome-like symptoms and symptoms
of anxiety/depression in patients with ulcerative colitis versus
control subjects
Ulcerative colitis





Total score 6.0 10.5 0.062
Abdominal pain 0.5 0.5 0.57
Bloating 1.0 1.0 0.19
Diarrhoea 0.5 0.5 0.38
Constipation 0.0 0.5 0.048*
Satiety 0.0 0.0 0.14
Median HADS scores
Anxiety 4.0 4.0 0.52
Depression 2.0 2.0 0.99
*Statistically significant
For the specific IBS symptoms the table presents the total score for each
cluster divided by number of items for each cluster
Ulcerative colitis in remission was defined by steroid-free clinical remission,
a Mayo Score ≤ 1 on endoscopy, a fecal calprotectin ≤ 200 μg/g and no
significant active inflammation on colon biopsies.
GSRS-IBS Gastrointestinal symptoms rating scale for irritable bowel syndrome,
HADS Hospital anxiety and depression scale
Table 3 Correlations between irritable bowel syndrome-like
symptoms and faecal calprotectin in patients with ulcerative
colitis and in control subjects
Ulcerative colitis
in remission
(n = 55) rs (p-value)
Controls
(n = 33) rs (p-value)
Total GSRS-IBS score 0.214 (0.124) 0.190 (0.115)
Abdominal pain 0.003 (0.985) 0.084 (0.641)
Bloating 0.140 (0.308) 0.008 (0.967)
Diarrhoea 0.380 (0.004)* 0.050 (0.782)
Constipation −0.028 (0.839) 0.142 (0.431)
Satiety 0.107 (0.443) 0.210 (0.241)
*Statistically significant
Ulcerative coitis in remission was defined by steroid-free clinical remission,
a Mayo Score ≤ 1 on endoscopy, a fecal calprotectin ≤ 200 μg/g and no
significant active inflammation on colon biopsies.
GSRS-IBS Gastrointestinal symptom rating scale for irritable bowel syndrome
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proposed to be possible mechanisms [35]. In both patients
with IBS and in patients with UC in remission there is a
relationship between gut symptoms and symptoms of anx-
iety and depression [27, 31, 32]. In the present study we
could nearly confirm an overall correlation of both anxiety
and depression scores with IBS scores in the patients with
UC in remission.
There are some limitations in our study. Firstly, only 80
out of 216 patients contacted accepted to participate in the
study. An unknown number of patients contacted were
missed due to reduced personal staff in the summer
months at the endoscopy unit. A resistance and inconveni-
ence with leaving a stool sample before the bowel prepar-
ation could be a cause for drop-out in some subjects.
Secondly, in our study we used the GSRS-IBS question-
naire, which only focuses on symptoms during the last
week, and has its major role in screening for IBS-like symp-
toms in different populations. For a strict IBS diagnosis the
Rome III questionnaire is recommended. However, it has
been argued that the GSRS-IBS is more sensitive than the
Rome III and therefore tends to overestimate the preva-
lence of IBS [32]. Thirdly, the colonoscopies in our study
were performed as clinical routine, and therefore are not
rigorously standardized. In addition, the endoscopists may
have gotten information from the patients regarding
present GI-symptoms and were therefore not sufficiently
blinded to the patients’ symptoms.
It is well known that there are sex differences in IBS
symptoms with it being more common in women [36]. For
example, women report more constipation and somatic
discomfort than men. Also, there are sex differences in
autonomic and anti-nociceptive responses to visceral stim-
uli [37]. In our study there were significantly more women
in the control group than in the patient group which may
have influenced the results towards a higher IBS score in
the control subjects. The significantly higher scores of
symptoms of constipation in the control group may be
contributed to the female dominance in the control group.
However, the GSRS-IBS score among the controls in the
present study is representative and is similar to that seen in
control subjects in other studies [38].
Conclusions
In conclusion, patients with UC in remission using strict
criteria for remission and with longstanding disease do not
have more IBS-like symptoms than controls. A moderate
correlation exists between FC levels and diarrhoea symptom
scores also in UC patients in remission.
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